LIGAN MP – Genomics and Metabolic Diseases Platform
the LIGAN-PM platform is dedicated to next-generation sequencing and other state-of-the-art genomic technologies. Our sequencing and genotyping systems are primarily dedicated to precision medicine. However, the platform is opened to all applications related to genetics and genomics regardless of species. This platform includes several sequencing systems (MiSeq, NextSeq, NovaSeq), various robots for library preparation, a platform dedicated to genotyping and other state-of-the-art systems of genetics and genomics (such as NanoString).
Go@L is the genomic plateforme of the UAR (Unité d’Appui et de Recherche) PLBS (Plateformes Lilloises en Biologie & Santé) UMS2014 US41. This plateforme is composed of 2 laboratories, one team (GFS) at the CHRU and one team (TAG) at the Institute Pasteur de Lille. The plateforme is specialized in genomic and transcriptomic based on the use and development of molecular biology applications using high throughput sequencing technologies.
Our main applications are :
– Genomic : WGS, WES, amplicon-seq, Tn-seq, CGH-arrays.
– Transcriptomic : RNA-seq, sRNA-seq, bacterial RNA-seq, NGS-RACE, RNA-seq full-length, DGE, single-cell RNA-seq, spatial transcriptomic.
– Metagenomic : targeted bacterial 16S metagenomic
The Animal Experimentation and High Technology Platform (PLEHTA) is specialized in hosting and establishing rodent animal models under highly controlled containment conditions. The platform includes multiple animal facilities (SPF, SOPF, biosafety levels 2 and 3), allowing maximum flexibility for the wide variety of demands by research groups from different disciplines including infections, cardiovascular and neurodegenerative diseases, metabolism, oncology, pharmacology and toxicology.
The BioImaging Center Lille (BICeL) is the academic platform for imaging, histology and cytometry of the University Hospital Campus, the Faculty of Science and Technology and the Pasteur Institute of Lille.
The BICeL brings together expertise, know-how and equipment on four platforms: (1) cytometry & flow imaging, (2) histology, (3) biophotonics and (4) electronic microscopy. Research & development in imaging techniques extends from the cell, to tissues and small rodent and aquatic organisms
The platform has transverse and diversified expertise. Its scientific scope includes in particular :
-Omics data analysis (genomics, transcriptomics, proteomics, metagenomics, epigenetics, …)
-Sequence annotation
-Integrative biology
-Systems biology
-Image data analysis
-High content screening data analysis
-Phylogeny
-Structural bioinformatics
The NMR laboratory is a technical platform of the Institut Pasteur de Lille. The laboratory is equipped with a 600MHz spectrometer with cryo-probe and sample changer, as well as a 300MHz spectrometer equipped with a sample changer.
The 300MHz low-field spectrometer is dedicated to the analytical control of small molecules to allow a fine analytical characterization of synthesized compounds or isolated natural products. Users can access it after having received training in its use
PAGés-P3M is the glycomic and proteomic plateforme of the UAR (Unité d’Appui et de Recherche) PLBS (Plateformes Lilloises en Biologie & Santé) UMS2014 US41. This plateforme is composed of 2 laboratories, one team (PAGés) at the Cité scientifique and one team (P3M) at the Institute Pasteur de Lille.
P3M offers expertise ranging from the identification of proteomes by nanoLC-MSMS and the use of databases or de novo analysis, to their quantification with or without labeling.
The plateforme develops Thermal Proteome Profiling (TPP) analysis for the identification of interactomes involved in the action of drugs, metabolic pathways, or even modulation of gene expression.
The available equipment also allows the study of post-translational modifications (PTM) of small sizes with or without enrichment, as well as the characterization of protein maturation events.
P3M collaborates with PAGés platform for the specific study of glycosylations at the scale of sugars, glycopeptides and glycoproteins.
The platform’s ambition is to develop serological or antigenic in vitro diagnostic test (IVD) as fast as possible, since 2020 for SARS-CoV-2, today for other viral, microbial or parasitic infectious agents, and tomorrow for global health applications on human, animal and environmental samples. The cross-disciplinary talents of our team weave together physics, chemistry, biology and engineering to imagine and design these diagnostic health tests of the future.
Mutualized Platform for Microbiology (P2M) is open to all the reference laboratories of the Institut Pasteur, in Paris and within the Pasteur Network, providing easy access to next generations multi-pathogenic sequencing (Illumina and Ion Torrent technologies).
The Platform was created in 2015 and has extensive experience of multipathogen sequencing.
Results can be downloadable remotly and sequence analysis can be carried out by the HUB bio info of the Institut Pasteur in Paris on request.